Valeant Pharmaceuticals makes management change

In its US Dermatology and Gastrointestinal businesses

Valeant Pharmaceuticals has confirmed that Deb Jorn has resigned as Executive Vice President, Company Group Chairman. In this role, she was responsible for running the company's US Dermatology and Gastrointestinal businesses.

Eric Abramson, Vice President Dermatology & Immunology Marketing, has been appointed General Manager of the US Dermatology business and Dr Ari Kellen, Executive Vice President and Company Group Chairman will oversee Valeant's gastrointestinal business.

You may also like

Finance

Sobi enters into new distribution agreement with Valeant for Ammonul

The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
You need to be a subscriber to read this article.
Click here to find out more.
Media

A precision medicine approach to developing cancer vaccines

Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah Houlton
Design & Build

Valeant Canada expands with $27.5m investment

The company will expand manufacturing and exporting capacity in Steinbach, Manitoba and Laval, Quebec
Regulatory

Opinion: Politics, passion and patient power

Did political correctness play a greater role than therapeutic efficacy in the FDA's decision to approve the 'pink Viagra'?
Finance

Valeant Pharmaceuticals to acquire Synergetics USA

Acquisition will further enhance Bausch + Lomb's presence around the world in the rapidly evolving field of vitreoretinal surgery
Finance

Valeant Pharmaceuticals to buy Sprout Pharmaceuticals for US$1bn in cash

Acquires FDA-approved 'female Viagra' pill Addyi and enters female health sector
Finance

Valeant to acquire Amoun Pharmaceutical

Valeant intends for Amoun to serve as a platform for further expansion into the broader Middle East and North African pharmaceutical market
Subscribe now